Signal of Benefit for Stem Cell Therapy in Progressive MS  Medscape

Read this article:
Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape

This Swedish startup wants to reduce the cost, and controversy, around stem cell production  TechCrunch

See the original post:
This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch

Woman, 22, With Leukemia Recalls Symptoms And New Treatment She Received: EXCLUSIVE  TODAY

Go here to see the original:
Woman, 22, With Leukemia Recalls Symptoms And New Treatment She Received: EXCLUSIVE - TODAY

Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report ...  Nature.com

Go here to see the original:
Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report ... - Nature.com

Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor ...  Nature.com

Read the original:
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor ... - Nature.com

Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated ...  Nature.com

See the rest here:
Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated ... - Nature.com

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the ...  Nature.com

Link:
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the ... - Nature.com

Iron Limitation Preserves Youthfulness of Blood Stem Cells  Mirage News

See the article here:
Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News

How an MS friendship led to HSCT and a love of running  Multiple Sclerosis News Today

More here:
How an MS friendship led to HSCT and a love of running - Multiple Sclerosis News Today

A dive into the genetic history of India, and the role of vitamin A in skin repair  Science

Continue reading here:
A dive into the genetic history of India, and the role of vitamin A in skin repair - Science

Vitamin A could have a key role in both stem cell biology and wound healing: Study  Medical Dialogues

More here:
Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.

More here:
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Press Release

Follow this link:
Mendus to hold Business Update event on March 12

BETHESDA, Md., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM), a cybersecurity and software services company focused on the federal government, announces that it has closed its previously announced $4 million financing with Live Oak Bank.

See the rest here:
Castellum, Inc. Announces Closing of $4 Million Revolver with Live Oak Bank

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) that showed patients who initiated ORLADEYO experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of the severity of their disease, their history of prior prophylaxis or their C1-inhibitor (C1-INH) level and function.

Originally posted here:
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat)...

CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene. If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Read the original post:
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe

Read the original here:
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI

Link:
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET

Continue reading here:
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge® (omidubicel-onlv)

Go here to read the rest:
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®